期刊文献+

血小板输注效果的临床观察 被引量:4

Observation on Clinical Effects of Platelet Transfusion
下载PDF
导出
摘要 目的通过对临床输注血小板前后相应指标的测定,观察其输注效果,分析输注血小板前的临床指征对血小板增值的影响。方法对64例各类患者输注前后24 h用细胞计数仪计数血小板,计算血小板的校正增值计数(CCI),观察64例患者101例次输注血小板的疗效。结果按输注后24 h CCI计算,血小板输注无效发生率36.63%,血小板相关抗体检出率37.84%。在回归分析中是否反复输注血小板(X1)、是否有出血表现(X2)、血小板相关抗体(X3)成为血小板输注前主要的临床指征。结论临床输注血小板前血小板基数变异较大,存在滥用的情况;输注血小板的治疗效果与输注次数呈正相关,而且随着输注次数的增加,血小板抗体产生的概率增加;X1、X2、X3是影响临床输注疗效的主要因素,要提高治疗效果最好的办法是制定出统一的临床血小板输注指征。 Objective Through the determination of appropriate indicators before and after clinical platelet transfusion, observe its infusion effect, analyze the clinical indication before platelet transfusion to effect platelet increment. Methods 64 patients of 24h before and after infusion use cell counting instrument to calculate the corrected count increment platelet(CCI) ,observe the efficacy of platelet transfusion in 64 patients with 101 cases. Results According to the calculation of 24 h corrected count increment after infu- sion,the platelet transfusion refractoriness incidence of platelet transfusion is 36.63% ,the detection rate of ptatelct-associated antibody is 37.84%. In regression analysis,the X1 ,X2 ,X3 become the main clinical indications to platelet transfusion. Conclusion The platelet radix before clinical platelet transfusion is larger variation,there exist abuse; the therapeutic effect of platelet transfusion is positively correlated to infusion frequency, with the increase of infusion, the probability of platelet antibody will increase; X1, X2, X3 are the main factors to impact the clinical infusion efficacy, the best approach to improve therapeutic effect is to develop an unified clinical platelet transfusion indication.
出处 《医学综述》 2009年第9期1431-1434,共4页 Medical Recapitulate
关键词 血小板输注 血小板抗体 效果观察 Platelet transfusion Antibodies Curative effect
  • 相关文献

参考文献12

二级参考文献36

  • 1刘达庄,包于勤.简易致敏红细胞血小板血清学技术的研究和应用[J].中华血液学杂志,1993,14(12):642-644. 被引量:36
  • 2刘达庄.血小板血型[A].见:王培华主编.输血技术学[C].北京:人民卫生出版社,1998.181~184.
  • 3Charles A. Schiffer, Kenneth C. Anderson, Charles L.Bennett, et al: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 2001, 19 (5) :1519-1538.
  • 4Hannes Wandt, Gerhard Ehninger, Walter Michael Gallmeier et al: New strategies for prophylactic platelet transfusion in patients with hematologic diseases. The Oncologist, 2001, 6(5):446-450.
  • 5Alcorta I, Pereira A, Ordinas A, et al. Clinical and laboratory factors associated with transfusion refractorieness a case-control study. Br J Haematol, 1996, 93(1) :220-224.
  • 6Gil-Fernandez J J, Alegre A, Fernandez-Villalta M J,et al. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant, 1996, 18(5) :931-935.
  • 7BernsteinS H, Nademanee A P, Vose J M, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood, 1998, 91(9) :3509-3517.
  • 8Nemo S, Swan V, Enger C, et al. Acute bleeding after bone marrow transplantation (BMT): Incidence and effect on survival-A quantitative analysis in 1 402 patients. Blood, 1998, 91(4) : 1469- 1477.
  • 9Hogge DE,Dutcher JP,Aisner J,et al.Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion.Am J Hematol,1983,14:363
  • 10Freedman J.Random donor platelet crossmatching.Curr Stud Hematol Blood Transfusion,1986,(52):65

共引文献89

同被引文献35

  • 1程洪波,李国良,熊丽红,周桂秀,罗敏智,魏宇靖,王晓莉.影响血小板输注疗效的多因素分析[J].江西医学检验,2007,25(2):119-121. 被引量:9
  • 2王振义.出血性疾病总论[M]//邓家栋.邓家栋临床血液学.上海:上海科学技术出版社,2001:1257-1311.
  • 3王李洁,刘风华,刘香.71例血小板输注疗效临床观察.检验医学与临床.2012,9(4):470-471.
  • 4Sherrill JS. Evidence-based platelet transfusion guidelines[J].Hematology Am Soc Hematol Educ Program,2007,(1):172-178.
  • 5Aline AF,Roberto Z,Sheila S. Identification of plate-let refractoriness in oncohematologic patients[J].Clinics (Sao Paulo),2011,(1):35-40.
  • 6Hod E,Schwartz J. Platelet transfusion refractoriness[J].Br J H aematol,2008,(3):348-360.
  • 7Neil B,Joanna M H,Gordon LP. Platelet transfusions:trig-ger,dose,benefits,and risks[J].Med Rep,2010,(5):1-5.
  • 8Pavenski K,Freedman J,Semple JW. HLA alloimmuniza-tion against platelet transfusions:pathophysiology,signifi-cance,prevention and management[J].{H}Tissue Antigens,2012,(4):237-245.
  • 9Seema RP,James CZ. Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens[J].Trans f us Med Rev,2013,(3):15-20.
  • 10Pereira J,Bronfman L,Bertin P. Platelet alloimmuniza-tion in patients with oncologic blood disorders treated with multiple transfusions:prospective study in adults and chil-dren[J].Rev Med Clinics,1997,(11):1305-1312.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部